{
    "clinical_study": {
        "@rank": "3237", 
        "arm_group": {
            "arm_group_label": "carfilzumib", 
            "arm_group_type": "Experimental", 
            "description": "Carfilzomib at a dose of 20mg/m2 I.V.  will be administrated at day 1, 2 post infusion of the stem cell (SC) graft to the first 10 patients. If no > grade II toxicity* the next 10 patients will receive Carfilzomib (27 mg/m2) at day 1,2 and 8, 9, 15 and 16. If no > grade II toxicity*  the next 10 patients will receive 2-3 cycles of Carfilzomib (27 mg/m2) administered at day 1,2 8,9,15 and 16 post SC graft infusion."
        }, 
        "brief_summary": {
            "textblock": "The aim of this study is to evaluate the safety and efficacy of Carfilzumib, which is a\n      novel biological agent used in the treatment of multiple myeloma in preventing\n      graft-versus-host disease, after stem cells transplantation from unrelated donors."
        }, 
        "brief_title": "Carfilzomib for the Prevention of Graft Versus Host Disease", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Graft-versus-host Disease", 
        "condition_browse": {
            "mesh_term": "Graft vs Host Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients with MDS/AML\n\n          2. 18 years or older and willing and able to comply with the protocol requirements.\n\n          3. LVEF \u2265 40%. 2-D transthoracic echocardiogram (ECHO) is the preferred method of\n             evaluation. Multigated Acquisition Scan (MUGA) is acceptable if ECHO is not\n             available.\n\n          4. Patients undergoing 8-10/10 HLA matched unrelated and unmanipulated PBSC\n             transplantation\n\n          5. Patients conditioned with reduced intensity or reduced toxicity conditioning i.e.\n             Fludarabine combine with Treosulfan or 2-4 days of I.V Busulfan.\n\n          6. Patients must sign written informed consent.\n\n          7. Adequate birth control in fertile patients.\n\n        Exclusion Criteria:\n\n          1. Patients undergoing other type of transplantation or with other type of basic disease\n             other than AML or MDS.\n\n          2. Patients with respiratory failure (DLCO < 30%).\n\n          3. Active congestive heart failure (New York Heart Association [NYHA] Class III to IV),\n             symptomatic ischemia, or conduction abnormalities uncontrolled by conventional\n             intervention.\n\n          4. Patients with > grade II liver renal toxicity.\n\n          5. Psychiatric conditions/disease that impair the ability to give informed consent or to\n             adequately co-operate\n\n          6. Bilirubin   > 3.0 mg/dl, transaminases > 3 times upper normal limit\n\n          7. Creatinine > 2.0 mg/dl\n\n          8. ECOG-Performance status > 2\n\n          9. Uncontrolled infection\n\n         10. Pregnancy or lactation\n\n         11. CNS disease involvement\n\n         12. Pleural effusion or ascites > 1 liter."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01991301", 
            "org_study_id": "SHEBA-12-9997-AN-CTIL"
        }, 
        "intervention": {
            "arm_group_label": "carfilzumib", 
            "description": "carfilzumib will be added to the standard regimen of drugs for prevention of graft-versus-host disease.", 
            "intervention_name": "carfilzumib", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "graft-versus-host disease", 
            "stem cell transplantation", 
            "matched unrelated donors", 
            "proteosmoe inhibitor", 
            "carfilzumib"
        ], 
        "lastchanged_date": "November 18, 2013", 
        "location": {
            "contact": {
                "email": "a.nagler@sheba.health.gov.il", 
                "last_name": "Arnon Nagler, MD", 
                "phone": "972 3 530 5830"
            }, 
            "contact_backup": {
                "email": "ashimoni@sheba.health.gov.il", 
                "last_name": "Avichai Shimoni, MD", 
                "phone": "972 3 530 5830"
            }, 
            "facility": {
                "address": {
                    "city": "Tel-Hashomer", 
                    "country": "Israel", 
                    "zip": "52621"
                }, 
                "name": "Chaim Sheba Medical Center"
            }, 
            "investigator": {
                "last_name": "Arnon Nagler, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Safety and Efficacy of Carfilzomib -a Novel Proteasome Inhibitor- for the Prevention of Acute Graft Versus Host Disease", 
        "overall_contact": {
            "email": "a.nagler@sheba.health.gov.il", 
            "last_name": "Arnon Nagler, MD", 
            "phone": "972 3 530 5830"
        }, 
        "overall_contact_backup": {
            "email": "ashimoni@sheba.health.gov.il", 
            "last_name": "Avichai Shimoni, MD", 
            "phone": "972 3 530 5830"
        }, 
        "overall_official": {
            "affiliation": "Chaim Sheba Medical Center", 
            "last_name": "Arnon Nagler, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Israeli Health Ministry Pharmaceutical Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We will evaluate the incidence of acute GVHD, grading and organ involvementBY STANDARD INTERNATIONAL CRITERIA.", 
            "measure": "incidence of acute graft-versus host disease", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01991301"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "We will evaluate the progression of acute graft-versus-host disease to chronic graft-versus-host disease and the grading and organ involvement.", 
                "measure": "incidence of chronic graft-versus-host disease", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "We will evaluate overall and disease-free survival after stem cell transplantation", 
                "measure": "survival rate", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Sheba Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sheba Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}